Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
Human platelets are known to possess 5HT2 receptors which, when activated, amplify the aggregation response produced by other aggregating agents. Several 5HT2 receptor antagonists, including ketanserin and ritanserin, are known to antagonize serotonin-mediated aggregation of human platelets. In the present study, we document the ability of three ergoline 5HT2 receptor antagonists, LY53857, sergolexole, and LY237733, to antagonize the serotonergic component of the human platelet aggregation response. Potencies of the ergoline esters (LY53857 and sergolexole) and the ergoline amide (LY237733) to inhibit serotonin-amplified platelet aggregation responses were similar to the potencies of ketanserin and ritanserin under the conditions of our study. Furthermore, all five 5HT2 receptor antagonists were capable of fully inhibiting the serotonergic component of the platelet aggregation response. In contrast to these potent ergoline esters and amides, 1-isopropyl dihydrolysergic acid (up to 10(-5)M), a putative metabolite of the ergoline esters, was ineffective under these in vitro conditions. These data are consistent with the high potency of these ergolines as antagonists of 5HT2 receptors and further support the involvement of 5HT2 receptors on human platelets in the amplifying response to serotonin.
McBride
P A
PA
Laboratory of Psychopharmacology, Cornell University Medical College, New York, New York 10021.
Mann
J J
JJ
Nimchinsky
E
E
Cohen
M L
ML
D000328:Adult; D004873:Ergolines / Q000494:pharmacology; D005260:Female; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology; D008237:Lysergic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D010880:Piperidines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects*; D016713:Ritanserin; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*
D004873:Ergolines; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D016713:Ritanserin; D012701:Serotonin; C062146:1-isopropyldihydrolysergic acid; D007650:Ketanserin; C066736:amesergide; D008237:Lysergic Acid; C054583:sergolexole; C032663:LY 53857